These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34716048)

  • 1. Re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy Have Therapeutic Benefit for Node-positive Upper Tract Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In press. https://doi.org/10.1016/j.urolonc.2021.07.029: A Plea for Uniform Terminology for Patients with Urothelial Carcinoma Treated with Chemotherapy Before Consolidative Surgery with Curative Intent: Induction Versus Neoadjuvant Chemotherapy.
    Liedberg F; Abrahamsson J; Bobjer J
    Eur Urol; 2022 Jan; 81(1):e18-e19. PubMed ID: 34716048
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Fredrik Liedberg, Johan Abrahamsson, and Johannes Bobjer's Letter to the Editor re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy have Therapeutic Benefit for Node-positive Upper Tract Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In press. https://doi.org/10.1016/j.urolonc.2021.07.029: A Plea for Uniform Terminology for Patients with Urothelial Carcinoma Treated with Chemotherapy Before Consolidative Surgery with Curative Intent: Induction Versus Neoadjuvant Chemotherapy: Need for Debate on the Optimized Treatment Strategy for Node-positive Upper Tract Urothelial Carcinoma.
    Shigeta K; Matsumoto K; Oya M
    Eur Urol; 2022 Jan; 81(1):e20-e21. PubMed ID: 34716047
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Siobhan P. Lynch, Yu Shen, Ashish Kamat, et al. neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.020.
    Ismaili N
    Eur Urol; 2012 Sep; 62(3):e65-6. PubMed ID: 22682991
    [No Abstract]   [Full Text] [Related]  

  • 4. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
    Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Arita Y; Akita H; Jinzaki M; Kikuchi E; Oya M
    Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A plea for uniform terminology for patients with urothelial carcinoma treated with chemotherapy prior to radical cystectomy: induction versus neoadjuvant chemotherapy.
    Liedberg F; Gudjonsson S; Kollberg P; Ullén A
    Eur Urol; 2015 Oct; 68(4):742-3. PubMed ID: 26047581
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2: The Conflict of Adding Immunotherapy to Chemotherapy in Metastatic Urothelial Carcinoma: A Matter of the Right Timing?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2021 Oct; 4(5):854. PubMed ID: 34535421
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
    Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
    Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
    Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
    J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.
    Porten S; Siefker-Radtke AO; Xiao L; Margulis V; Kamat AM; Wood CG; Jonasch E; Dinney CP; Matin SF
    Cancer; 2014 Jun; 120(12):1794-9. PubMed ID: 24633966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
    Tabayoyong W; Li R; Gao J; Kamat A
    Urol Clin North Am; 2018 May; 45(2):155-167. PubMed ID: 29650132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7.: Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
    de Jong JJ; Gibb EA
    Eur Urol; 2022 Apr; 81(4):e90-e91. PubMed ID: 35034800
    [No Abstract]   [Full Text] [Related]  

  • 12. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.
    Urakami S; Yuasa T; Yamamoto S; Sakura M; Tanaka H; Hayashi T; Uehara S; Inoue Y; Fujii Y; Masuda H; Fukui I; Yonese J
    Int J Clin Oncol; 2015 Dec; 20(6):1171-8. PubMed ID: 25953680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
    Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Eriksson P; Kollberg P; Marzouka NA; Höglund M; Ullén A; Liedberg F
    Eur Urol; 2022 Apr; 81(4):e92-e93. PubMed ID: 35039183
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Hensley PJ; Kamat AM
    Eur Urol; 2022 Mar; 81(3):316-317. PubMed ID: 35039182
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017: Focus on Our Personal Recollections and Observations.
    Montironi R; Scarpelli M; Cimadamore A; Mikuz G
    Eur Urol Focus; 2022 May; 8(3):882-884. PubMed ID: 33994166
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Achkar T; Parikh RA
    Urol Clin North Am; 2018 May; 45(2):257-266. PubMed ID: 29650141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
    Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
    Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 predicts response to neoadjuvant chemotherapy and is overexpressed in lymph node metastases of urothelial cancer of the bladder.
    Kiss B; Skuginna V; Fleischmann A; Bell RH; Collins C; Thalmann GN; Seiler R
    Urol Oncol; 2015 Apr; 33(4):166.e1-8. PubMed ID: 25596645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Mathieu Rouanne, Dean F. Bajorin, Raquibul Hannan, et al. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol 2020;3:728-38.
    Montorsi F; Martini A
    Eur Urol Oncol; 2021 Apr; 4(2):336. PubMed ID: 33541839
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.